← Markets

Capricor Therapeutics, Inc.

CAPR · NASDAQ

Market closed$19.44$0.320000 (+1.67%)After hours $19.54 · +0.51%

Key statistics

Previous close$19.12
Open$18.77
Day high$19.79
Day low$18.70
52-week high$40.37
52-week low$4.30
Market cap888.74M
Volume1.17M
Average volume1.23M
P/E ratio-8.38
Forward P/E—
EPS-2.32
Dividend yield0.00%

Market context

Why it moved

CAPR shares edged higher amid continued investor interest following the company's ongoing legal battle with NS Pharma over the commercialization of its DMD therapy Deramiocel, with the market appearing to stabilize as traders assess the implications of the dispute ahead of a key FDA review.

BitgetStocktwitsInstagramDigitalappliedStocktitan

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Capricor Therapeutics rose nearly 2%, with investors increasingly focused on the company's approaching August 22 FDA decision date for Deramiocel, its cell therapy for Duchenne muscular dystrophy. The stock advanced despite broader healthcare sector pressure and a weak day for the S&P 500, as biotech sentiment benefited from UBS's upgraded outlook on the sector and optimism around M&A and product catalysts. Capricor's BLA resubmission — backed by Phase 3 HOPE-3 data showing a 54% slower decline in upper-limb function and a 91% reduction in cardiac disease progression — remains the central catalyst for investors, with the stock also supported by reports that a former Capricor executive is being considered for a senior FDA leadership role.

1.6736

July 17, 2026Capricor Therapeutics tumbled amid elevated volume, with investors closely watching the company's ongoing legal dispute with commercialization partner NS Pharma over Deramiocel's pricing structure, alongside the high-stakes FDA PDUFA date of August 22 for its DMD therapy. The lawsuit — filed in May alleging NS Pharma failed to prepare for Deramiocel's commercial rollout and refused to fix Medicare reimbursement pricing flaws — continues to weigh on sentiment, even as the broader healthcare sector saw a lift from UnitedHealth Group's strong Q2 earnings beat.

-6.0442

July 16, 2026Capricor Therapeutics declined as investors reassess positioning ahead of the August 22 FDA decision on Deramiocel, its Duchenne muscular dystrophy therapy. The stock remains in focus after a high-stakes comparison piece pitted it against Sarepta in the DMD space, with the FDA review resuming earlier this year following a July 2025 Complete Response Letter. The broader healthcare sector (XLV) also edged lower, though UBS highlighted biotechs as a key allocation theme benefiting from stabilizing regulation and M&A tailwinds.

-1.5957

July 15, 2026Capricor Therapeutics edged higher in regular trading and extended gains in after-hours, with shares rising 1.74% post-close amid investor focus on the pivotal August 22 FDA decision on Deramiocel for Duchenne muscular dystrophy. Key developments shaping sentiment include a May lawsuit against commercial partner NS Pharma over pricing and rollout concerns, and April's AAN conference presentation of Phase 3 HOPE-3 trial data showing a 54% slower decline in upper-limb function. The broader healthcare sector (XLV) also edged up in after-hours, supported by a cooler-than-expected June CPI print lifting risk appetite across markets.

0.3396

July 11, 2026Capricor Therapeutics fell 4.40% as investors weigh a complex risk-reward setup ahead of its pivotal August 22 FDA decision on Deramiocel for Duchenne muscular dystrophy. The overhang from Capricor's May lawsuit against commercial partner NS Pharma — alleging failure to prepare for launch and Medicare pricing flaws — continues to cloud sentiment, even as Cantor Fitzgerald maintained a Buy rating with a $62 price target on July 8, well above the analyst consensus of $53. Shares edged slightly higher in after-hours trading, while broader biotech sentiment remains constructive with Jim Cramer calling the space the market's hottest group.

-4.4

July 9, 2026Capricor Therapeutics closed essentially flat as investors weighed a confluence of catalysts ahead of a pivotal FDA advisory committee meeting on July 29 for its Duchenne muscular dystrophy cell therapy Deramiocel. Cantor Fitzgerald reiterated a Buy rating with a $62 price target on Tuesday, reinforcing the Strong Buy analyst consensus with a $53 average target — implying over 136% upside — even as the stock has pulled back significantly from recent highs after its removal from Russell indexes and an ongoing lawsuit against commercial partner NS Pharma over commercialization pricing concerns. The broader biotech sector continues to provide a tailwind, with Jim Cramer calling it "the hottest group in the market" and capital rotating into healthcare from semiconductors, while the July 29 FDA adcom and the August 22 PDUFA date remain the key near-term binary events for CAPR investors.

0.135

July 7, 2026Capricor Therapeutics edged lower in regular trading but is rebounding in after-hours, as investors focus on the upcoming July 29 FDA advisory committee meeting for Deramiocel, its Duchenne muscular dystrophy cell therapy. The stock was pressured during the session following its removal from several Russell indexes, though analysts note the index exit doesn't alter the core risk-reward picture ahead of the Aug. 22 FDA PDUFA decision. The broader biotech backdrop is increasingly favorable, with Jim Cramer calling the sector "the hottest group in the market" and M&A activity accelerating under a more permissive regulatory environment — a tailwind for late-stage DMD asset holders like Capricor.

-0.9362

July 7, 2026Capricor Therapeutics closed down roughly 3.4% in above-average volume, as the broader healthcare sector also faced headwinds on the day. Investor focus remains squarely on the upcoming FDA decision for Deramiocel — the company's DMD therapy — with a PDUFA target date of August 22. Adding complexity, Capricor is locked in a legal dispute with commercial partner NS Pharma over pricing terms that the company argues could make the therapy commercially unviable under Medicare reimbursement rules. In after-hours trading, shares recovered modestly, rising about 1.9%, as a comparison piece weighing Capricor against DMD peer Sarepta circulated ahead of what analysts are calling a high-stakes week for the space.

-3.3606

Stocktwits · July 17, 2026Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside?Simply Wall Street · July 17, 2026Capricor Therapeutics (CAPR) Signs Expansion Lease Tied To Deramiocel FDA ApprovalCoStar · July 16, 2026News | Capricor signs San Diego’s largest biotech lease of the yearStock Titan · July 14, 2026Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ leasePharma Voice · July 13, 2026Moderna, Takeda and Capricor on the verge of notching big drug approvalsStocktwits · May 8, 2026CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA ReviewStock Titan · May 4, 2026Biotech Capricor pairs Q1 results with a corporate update May 12Stocktwits · March 5, 2026CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains
Mt Newswire · June 29, 2026Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy
Benzinga · June 26, 2026What's Going On With Capricor Therapeutics Stock On Friday?
Benzinga · June 26, 2026Capricor Therapeutics Announces FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Intends To Call Advisory Committee Meeting To Discuss Capricor's BLA Of Deramiocel For Duchenne Muscular Dystrophy Treatment
Benzinga · June 26, 2026Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference
Benzinga · May 12, 2026Capricor Therapeutics Q1 2026 Earnings Call Transcript
Mt Newswire · May 12, 2026Capricor Therapeutics Q1 Loss Widens
Mt Newswire · May 12, 2026Earnings Flash (CAPR) Capricor Therapeutics, Inc. Reports Q1 Revenue $0
Benzinga · May 8, 2026Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Peers

S&P 500SPX · $7,457.69-1.01%Sarepta Therapeutics, Inc.SRPT · $17.22-0.06%Entrada Therapeutics, Inc.TRDA · $6.89+0.29%REGENXBIO Inc.RGNX · $9.89-11.70%Wave Life Sciences Ltd.WVE · $5.82+2.65%Legend Biotech CorporationLEGN · $22.26-1.98%CRISPR Therapeutics AGCRSP · $47.78-1.63%Travere Therapeutics, Inc.TVTX · $56.71+2.59%Alterity Therapeutics LimitedATHE · $4.98-2.06%Belite Bio, IncBLTE · $150.08-0.39%Evaxion Biotech A/SEVAX · $3.08-1.44%Abeona Therapeutics Inc.ABEO · $7.00-0.28%